Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer

Cancer Investigation

Volumn 18, Issue 7, 2000, Pages 602-608

  Kasimis, Basil ^a   Wilding, George ^b   Kreis, Willie ^c   Feuerman, Martin ^a   Chang, Victor ^a   Hwang, Shirley ^a   Steafather, Harriet ^a   Cogswell, Janet ^a   Rae, Charlesworth ^a   Blumenfrucht, Marvin ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 20244390417     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009032826     Document Type: Article

References (36)

1. Cancer statistics
2. Studies on prostatic cancer: Effects of castration on advanced carcinoma of the prostate gland
3. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
4. Management of cancer of the prostate
5. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial
6. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
7. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients
8. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
9. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
10. Current chemotherapy and future directions in research for the treatment of advanced hormone refractory prostate cancer
11. Bicalutamide in the treatment of advanced prostate cancer carcinoma: A phase II non comparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy
12. Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma
13. Current clinical studies with a new nonsteroidal anti-androgen, Casodex
14. A randomized comparison of Casodex 150 mg versus castration in the treatment of advanced prostate cancer
15. Improvements in subjective response in patients with advanced prostate cancer treated with Casodex (bicalutamide) 150 mg monotherapy compared with castration
16. Bicalutamide (B) monotherapy versus flutamide (F) plus goserelin (G) in prostate cancer (CA) patients
17. Criteria for response to treatment of metastatic prostatic cancer
18. Nonparametric estimation for incomplete observations
19. Non parametric confidence limits for survival probabilities and median survival time
20. Sequential therapy with the antiandrogen Casodex (ICI 176334) and castration in patients with stage D2 prostate cancer: The results of castration
21. The Veteran Administration Cooperative Urologic Research Groups Studies of cancer of the prostate
22. Therapeutic options in treatment of advanced carcinoma of the prostate
23. Advanced prostatic carcinoma: Early versus late endocrine therapy
24. 2 prostate cancer treated with sequential bicalutamide 50 mg followed by androgen deprivation or androgen deprivation as initial therapy. Results of a randomized trial
25. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
26. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol
27. A new antiprostatic agent for treatment of prostatic carcinoma
28. Long-term experience with flutamide in patients with prostatic carcinoma
29. Novel androgen ablation in advanced prostatic carcinoma with minimal side effects: Early results
30. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
31. How much can we rely on the level of prostate specific antigen as an endpoint for evaluation of clinical trials? A word of caution
32. Chemotherapy with mitoxantrone plus prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
33. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer
34. Withdrawal phenomenon with the antiandrogen Casodex
35. The antiandrogen withdrawal syndrome
36. Bicalutamide in advanced prostate. A review